Product name: Aliskerin (Tekturna)
CAS: 173334-57-1
Molecular formula: C30H53N3O6
Molecular weight: 551.76
Description: Aliskiren  (trade names Tekturna, US; Rasilez, UK and elsewhere) is the first in a class of drugs called direct renin inhibitors. Its current licensed indication is essential (primary) hypertension.
Aliskiren was co-developed by the Swiss pharmaceutical companies Novartis and Speedel. It was approved by the US Food and Drug Administration in 2007 for the treatment of primary hypertension.
In December 2011, Novartis had to halt a clinical trial of the drug after discovering increased incidence of nonfatal stroke, renal complications, hyperkalemia, and hypotension in patients with diabetes and renal impairment (ALTITUDE Trial ).